Ab­b­Vie re­treats as Gala­pa­gos of­fers mixed PhII CF da­ta, leav­ing a ma­jor al­liance in per­il — Ver­tex shares surge

Gala­pa­gos $GLPG out­lined some dis­tinct­ly mixed re­sults from its Phase II study of its C2 cor­rec­tor GLPG2737 for cys­tic fi­bro­sis Thurs­day af­ter­noon, man­ag­ing to boost the prospects of ri­val Ver­tex in the process.

While Gala­pa­gos said that the drug — com­bined with a sta­ble dose of Ver­tex’s Orkam­bi — had hit a sig­nif­i­cant de­crease of 19.6 mmol/L (p=0.02) on sweat chlo­ride from base­line, there was on­ly a pos­i­tive trend in ppFEV1. “The mean ab­solute change from base­line in ppFEV1 for the GLPG2737 treat­ment arm ver­sus place­bo through day 28 was 3.4% (p=0.08).”

That’s not good. Just lis­ten to Baird’s Bri­an Sko­r­ney:

The lack­lus­ter FEV1 per­for­mance re­al­ly makes it tough to imag­ine Gala­pa­gos mount­ing a rel­e­vant com­pet­i­tive cam­paign against Ver­tex’s triple com­bi­na­tion. Re­call, each of Ver­tex’s third agents showed about a 10% im­prove­ment in FEV1 when added to Symdeko. We think Gala­pa­gos need­ed to cross 5% to even have a hope of an ar­gu­ment here but re­al­is­ti­cal­ly would need to get a ~10% ben­e­fit to re­al­ly be con­sid­ered a com­pet­i­tive threat. We think the door is clos­ing on Gala­pa­gos, which is look­ing less and less like­ly to be able to pull out a triple com­bo that could even hope to match Ver­tex’s, much less beat it.

And while Gala­pa­gos is pro­ceed­ing with a study of its triple ther­a­py (da­ta due in the next quar­ter), its big part­ner Ab­b­Vie $AB­BV has opt­ed out of a sec­ond triple study that had been con­tem­plat­ed, leav­ing Gala­pa­gos “re­view­ing the fu­ture of its CF col­lab­o­ra­tion with Ab­b­Vie.”

Ab­b­Vie al­ready pulled out of one al­liance with Gala­pa­gos, sur­ren­der­ing its in­ter­est in fil­go­tinib, which Gilead picked up. The bond can’t be too strong now. Ab­b­Vie paid Gala­pagis $40 mil­lion up­front to part­ner on CF, with more than $300 mil­lion in mile­stones on the ta­ble. And Ab­b­Vie has walked away from much more than that with­out a sec­ond thought.

An­a­lysts — par­tic­u­lar­ly some of the heavy­weights that have long been lined up on Ver­tex’s side — are like­ly to see this as an­oth­er vin­di­ca­tion of their star play­er as the un­chal­lenged leader in CF.  Just a few weeks ago Pro­teosta­sis was brushed aside as it tried to of­fer some com­pe­ti­tion.

But the mar­ket wasn’t hav­ing it — then or now.

Piet Wiger­inck

Thurs­day af­ter­noon Ver­tex shares shot up 9% in af­ter-mar­ket trad­ing as in­vestors sa­vored the idea that the big biotech had been left well out in front, with an undis­put­ed lead as it pur­sues its own triplets. Gala­pa­gos, mean­while, plunged 17% on the news.

But they’re forg­ing ahead, in a fash­ion.

“The PEL­I­CAN tri­al is the first to eval­u­ate GLPG2737 as a C2 cor­rec­tor in CF pa­tients on top of Orkam­bi and showed CFTR on-tar­get ac­tiv­i­ty with GLPG2737 in com­bi­na­tion with Orkam­bi,” said Dr. Piet Wiger­inck, chief sci­en­tif­ic of­fi­cer of Gala­pa­gos. “We have ini­ti­at­ed dos­ing in the FAL­CON tri­al, in which we aim to eval­u­ate high­er ex­po­sures of GLPG2737 in CF pa­tients and fur­ther un­der­stand the po­ten­tial syn­er­gis­tic ef­fect of GLPG2737 on top of our own dual com­bi­na­tion com­pounds.”

Nick Leschly via Getty

UP­DAT­ED: Blue­bird shares sink as an­a­lysts puz­zle out $1.8M stick­er shock and an un­ex­pect­ed de­lay

Blue­bird bio $BLUE has un­veiled its price for the new­ly ap­proved gene ther­a­py Zyn­te­glo (Lenti­Glo­bin), which came as a big sur­prise. And it wasn’t the on­ly un­ex­pect­ed twist in to­day’s sto­ry.

With some an­a­lysts bet­ting on a $900,000 price for the β-tha­lassemia treat­ment in Eu­rope, where reg­u­la­tors pro­vid­ed a con­di­tion­al ear­ly OK, blue­bird CEO Nick Leschly said Fri­day morn­ing that the pa­tients who are suc­cess­ful­ly treat­ed with their drug over 5 years will be charged twice that — $1.8 mil­lion — on the con­ti­nent. That makes this drug the sec­ond most ex­pen­sive ther­a­py on the plan­et, just be­hind No­var­tis’ new­ly ap­proved Zol­gens­ma at $2.1 mil­lion, with an­a­lysts still wait­ing to see what kind of pre­mi­um can be had in the US.


Glob­al Blood Ther­a­peu­tics poised to sub­mit ap­pli­ca­tion for ac­cel­er­at­ed ap­proval, with new piv­otal da­ta on its sick­le cell dis­ease drug

Global Blood Therapeutics is set to submit an application for accelerated approval in the second-half of this year, after unveiling fresh data from a late-stage trial that showed just over half the patients given the highest dose of its experimental sickle cell disease drug experienced a statistically significant improvement in oxygen-wielding hemoglobin, meeting the study's main goal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

News­mak­ers at #EHA19: Re­gen­eron, Ar­Qule track progress on re­sponse rates

Re­gen­eron’s close­ly-watched bis­pe­cif­ic con­tin­ues to ring up high re­sponse rates

Re­gen­eron’s high-pro­file bis­pe­cif­ic REGN1979 is back in the spot­light at the Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion sci­en­tif­ic con­fab. And while the stel­lar num­bers we saw at ASH have erod­ed some­what as more blood can­cer pa­tients are eval­u­at­ed, the re­sponse rates for this CD3/CD20 drug re­main high.

A to­tal of 13 out of 14 fol­lic­u­lar lym­phomas re­spond­ed to the drug, a 93% ORR, down from 100% at the last read­out. In 10 out of 14, there was a com­plete re­sponse. In dif­fuse large B-cell lym­phoma the re­sponse rate was 57% among pa­tients treat­ed at the 80 mg to 160 mg dose range. They were all com­plete re­spons­es. And 2 of these Cars were for pa­tients who had failed CAR-T ther­a­py.

Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

Now that J&J and Genmab have thrust Darzalex onto the regulatory orbit for first-line use in multiple myeloma, the partners are lining up a deal for a next-gen follow-on to the leading CD38 drug.

Janssen — J&J’s biotech unit — has its eyes on HexaBody-CD38, a preclinical compound generated on Genmab’s tech platform designed to make drugs more potent via hexamerization.

Genmab is footing the bill on studies in multiple myeloma and diffuse large B-cell lymphoma; once it completes clinical proof of concept, Janssen has the option to license the drug for a $150 million exercise fee. There’s also $125 million worth of milestones in play.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

Gene ther­a­pies seize the top of the list of the most ex­pen­sive drugs on the plan­et — and that trend has just be­gun

Anyone looking for a few simple reasons why the gene therapy field has caught fire with the pharma giants need only look at the new list of the 10 most expensive therapies from GoodRx.

Two recently approved gene therapies sit atop this list, with Novartis’ Zolgensma crowned the king of the priciest drugs at $2.1 million. Right below is Luxturna, the $850,000 pioneer from Spark, which Roche is pushing hard to acquire as it adds a gene therapy group to the global mix.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

Savara shares are crushed as PhI­II tri­al flunks pri­ma­ry, key sec­on­daries — but they can’t stop be­liev­ing

In­vestors are in no mood to hear biotechs tout the suc­cess of a “key” sec­ondary end­point when the piv­otal Phase III flunks the pri­ma­ry goal. Just ask Savara. 

The Texas biotech $SVRA went look­ing for a sil­ver lin­ing as com­pa­ny ex­ecs blunt­ly con­ced­ed that Mol­gradex, an in­haled for­mu­la­tion of re­com­bi­nant hu­man gran­u­lo­cyte-macrophage colony-stim­u­lat­ing fac­tor (GM-CSF), failed to spur sig­nif­i­cant­ly im­proved treat­ment out­comes for pa­tients with a rare res­pi­ra­to­ry dis­ease called au­toim­mune pul­monary alve­o­lar pro­teinosis, or aPAP.

As an­oth­er an­tibi­otics biotech sinks in­to a cri­sis, warn­ings of a sec­tor ‘col­lapse’

Another antibiotics company is scrambling to survive today, forcing the company’s founding CEO to exit in a reorganization that eliminates its research capabilities as the survivors look to improve on minuscule sales of their newly approved treatment. And the news — on top of an alarming series of failures — spurred at least one figure in the field to warn of a looming collapse of the antimicrobial resistance research field.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.

'We kept at it': Jef­frey Blue­stone plots late-stage come­back af­ter teplizum­ab shown to de­lay type 1 di­a­betes

Late-stage da­ta pre­sent­ed at the Amer­i­can Di­a­betes As­so­ci­a­tion an­nu­al meet­ing in 2010 pushed Eli Lil­ly to put a crimp on teplizum­ab as the phar­ma gi­ant found it un­able to re­set the clock on new­ly di­ag­nosed type 1 di­a­betes. At the same con­fer­ence but in dif­fer­ent hands nine years lat­er, the drug is mak­ing a crit­i­cal come­back by scor­ing suc­cess in an­oth­er niche: de­lay­ing the on­set of the dis­ease.

In a Phase II tri­al with 76 high-risk in­di­vid­u­als — rel­a­tives of pa­tients with type 1 di­a­betes who have di­a­betes-re­lat­ed au­toan­ti­bod­ies in their bod­ies — teplizum­ab al­most dou­bled the me­di­an time of di­ag­no­sis com­pared to place­bo (48.4 months ver­sus 24.4 months). The haz­ard ra­tio for di­ag­no­sis was 0.41 (p=0.006).

Bain’s biotech team has cre­at­ed a $1B-plus fund — with an eye to more Big Phar­ma spin­outs

One of the biggest investors to burst onto the biotech scene in recent years has re-upped with more than a billion dollars flowing into its second fund. And this next wave of bets will likely include more of the Big Pharma spinouts that highlighted their first 3 years in action.

Adam Koppel and Jeff Schwartz got the new life sciences fund at Bain Capital into gear in the spring of 2016, as they were putting together a $720 million fund with $600 million flowing in from external investors and the rest drawn from the Bain side of the equation. This time the external investors chipped in $900 million, with Bain coming in for roughly $180 million more.

They’re not done with Fund I, with plans to add a couple more deals to the 15 they’ve already posted. And once again, they’re estimating another 15 to 20 investments over a 3- to 5-year time horizon for Fund II.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.